Introduction
The era of randomized cancer clinical trials began in 1958 with the first use of systemic therapy following a radical mastectomy in the treatment of breast cancer. 1 In 2014 in Poland, there were 396 new clinical trials recorded. Approximately, 1/4 of patients in clinical trials in Poland are enrolled in oncology studies (23% in 2014). 2, 3 Oncology is a frequent area of clinical research in Poland due to many factors. Firstly, in Poland, access to the national healthcare system is limited, and medications are expensive; hence, with the offer of better medical care, free drugs and diagnostic procedures, patient recruitment in clinical trials is very high. This factor is particularly important when treating patients in areas where the availability of effective drugs is limited at this stage of the development of medicine (i.e., oncology). Secondly, the high motivation to participate in clinical trials may also result from the relatively long time patients have to wait to see a specialist in Poland. Participation in a clinical trial, therefore, significantly shortens the average time associated with receiving specialist care. Furthermore, it may be the case that, through clinical trials, subjects can access medicines that are not typically available in Poland.
Material and methods

Sample and place of study
The prospective study was conducted among 284 patients of Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology in Warszawa, Poland in 2014-2016. Patients were recruited to collect a mixture of tumor types (soft tissue sarcoma, bone sarcoma, malignant melanoma, gastrointestinal stromal tumor, breast cancer, and lung cancer) and cancer stages; study included patients who had never participated in a clinical trial. Exclusion criteria included age <18 years. We selected our sample on the basis of respondents' availability. We conducted the study with patients available at a given time and place at the Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology in Warszawa, based on the randomness of their visits to the Institute. The sample included patients of different sociodemographic data: age and gender, place of residence, marital status, and educational stage. Participation in the survey was voluntary and anonymous. Out of 284 selected patients, 256 (90%) agreed to participate in the study and completed the questionnaire. Analysis was based on responses from these 256 respondents. We analyzed all subjects as a group, regardless of the type of cancer.
Instruments
We applied the "Paper and Pencil Interview" (PAPI) technique. This survey-based study was performed using the authors' own questionnaire; it included 10 closed questions about the awareness and perceptions of clinical trials as well as single-and multiple-choice questions; 5 questions concerning demographic information. The majority of questions in our questionnaire were adapted from a literature review and previous similar studies. All the possible answers are shown in Tables 1-4 and Fig. 1 .
Ethics
The Ethical Committee consent for the presented research is not required. According to the statement of the Ethical Committee of the Medical University of Warsaw: "The Committee does not provide opinions on surveys, retrospective studies, or other non-invasive research." 
Data analysis
The data was collected in a Microsoft Excel database. Survey responses were aggregated into frequencies and percentages. Statistical analysis was performed using STA-TISTICA v. 10 software (StatSoft, Tulsa, USA). Descriptive statistics of respondent demographics, awareness of clinical trials, and a willingness to participate in clinical trials were analyzed. Associations among the variables were evaluated by χ 2 test. A value of p < 0.05 was considered statistically significant.
Results
Socio-demographic characteristics of patients
The study was performed in 256 patients with cancer, including 138 women (54%) and 118 men (46%). The mean age of respondents was 46 (range: 21-77 years). The main part of the population taking part in the study comprised married persons (44%); with regard to other previously mentioned sociodemographic data, 38% of patients had secondary education, and about 75% lived in an urban area. Table 1 presents the socio-demographic characteristics of the patient population.
Patients' attitudes towards clinical trials
In terms of knowledge and awareness of clinical trials, 69.9% of the participants had previously heard about clinical trials, but 64.8% had an interest in participating in cancer clinical trials, and only 53.9% had an interest in participating in clinical trials as healthy volunteers. Respondents were statistically more likely to decide to participate in a clinical trial as oncological patients than as healthy volunteers (Pearson's χ 2 test p = 0.00006). Other factors, including age, gender, educational level, and resident area were not significantly associated with willingness to participate in clinical trials (p > 0.05). Most The desire to qualify for clinical trials in no way depends on the knowledge of the side effects (Pearson's χ 2 test p = 0.16796).
The most frequent source of information about clinical trials was mass media (94%), other patients who took part in clinical trials before (46%), and physicians (37%) - Fig. 1 .
The survey group recognized the benefits of clinical trials, such as treatment that may be more effective than the standard approach (85.2%), and regular and careful attention from some of the best cancer doctors (10.2%). Among the more frequently cited barriers were the fear of possible side effects (69.1%) and frequent hospital visits (12.9%) - Table 3 .
Clinical trials were more often associated with positive factors; they were most often associated with the introduction of new therapy (62.1%) and the advancement of medical knowledge (46.1%). However, 46.1% of respondents indicated that patients in clinical trials are "treated like guinea pigs" - Table 4 .
Discussion
In our study, only 69.9% of respondents had previously heard about clinical trials. Similar results were obtained among rural Latinos, where that percentage was 68%. 5 However, a previous public opinion study conducted in Poland in 2004 (n = 1003) showed that only 28% of respondents, at any time, had heard about the clinical trials. 6 The differences in the results obtained in our country can be explained by the fact that our study was conducted 10 years later, which may indicate that clinical trials in Poland are more popularized now.
In this survey, 64.8% of the interviewed subjects indicated willingness to participate in cancer clinical trials; however, only 53.9% indicated willingness to participate in clinical trials as a healthy volunteer. In a study conducted in Saudi Arabia, 61% of the 117 interviewed subjects who were aware of clinical trials expressed their willingness to participate in them. 7 Nevertheless, in the study conducted in India, 58.9% of the participants expressed willingness to participate in clinical trials. 8 In another study in the United States, 44% of patients demonstrated willingness to participate or have already enrolled in clinical trials, whereas in the study in Great Britain (n = 1040), only 30.4% of the respondents conveyed their enthusiasm to participate in clinical trials. 9, 10 In a previously cited Polish study, the number of people willing to participate in a clinical trial with regard to disease increases about 5-fold compared with a desire to participate as a healthy volunteer (from 15% to 71%). 6 The potential benefit of participating in a clinical trial for an oncological patient is the access to promising new treatments often not available outside the clinical trial setting -this may explain the difference. Possibly, the main reason people lack willingness to participate in a clinical trial is that they are not aware that the studies are an option for them. Our research has shown that 60.2% of the patients had not discussed participating in clinical trials with their doctor. This is consistent with the results of another study indicating that 73% of patients did not recall discussing clinical trial participation with their doctor. 11 In our study, 84% of all respondents pointed to mass media as the most common source of information on clinical trials. For 46%, it were other patients who, prior to participation in clinical trials, were the primary source of that information. An American study from 2015 showed that people aware of clinical trials, most learned about clinical trials online (58%). 12 The Center for Information and Study on Clinical Research Participation (CISCRP), founded in 2013, showed that the Internet is the most common way of finding out about clinical trials.
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With regard to the recognition of clinical trials as important and necessary, 94.1% of the patients regarded clinical trials as useful, and admitted that participating in them can bring benefits; the respondents in a public opinion study also highly appreciated the need for clinical trials (71%). 6 The decision about whether to participate in clinical trial is very personal and depends on many factors, both positive and negative. In our study, one such factor is the fear of being treated like a guinea pig (46.1%); on the other hand, equal number of respondents considered that participating in a clinical study contributes to medical knowledge. In another Polish study, 88% of the public opinion established the fact that there could be advances in medicine as a result. 6 In addition, 62.1% of our study population stated that a clinical trial is conducted for the introduction 
Physician
Other Other patients with prior participation to clinical trials of a new treatment/new drug. In turn, in the OMNIBUS study conducted in May 2010, most respondents (35%) associated clinical trials with advances in medicine, and in a study by Shapiro et al., they also believed that clinical trials contribute to the development of medicine (63%). 14, 15 Clinical trials can offer benefits for many people with cancer. The patients in our study said that clinical trials are an alternative treatment for the disease -clinical trial treatment was thought to be better than the standard treatment (85.2%). Other studies have established that the most important benefits that encourage patients to participate in clinical trials are: the possibility of reducing one's chance of getting cancer and the possibility of preventing others from getting cancer in the future, the psychosocial benefits of trial participation, and also the possible benefit of treatment effectiveness. 16, 17 On the one hand, clinical trials are the basis for improvements in oncologic patient care, but on the other they have significant barriers. In our study, 69.1% of patients identified the fear of side effects as the greatest barrier to clinical trial participation, and 89.1% said that during clinical trials they may experience unexpected side effects. As many as 76% of the survey respondents of public opinion study claimed that participating in tests of a new drug may harm their health. 6 Other barriers that discouraged patients from participating in clinical trials are fear, mistrust of the medical community, discouragement from oncologist or family physician, financial burden, difficulties in commuting, and lack of information. 8 However, a survey done by the CISCRP in 2013 found that 94% of respondents believe clinical research is safe for those who participate in it.
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Conclusions
In conclusion, our study found that patient's awareness about clinical trials varied. However, a positive attitude towards research was visible. The main identified barrier was the fear of possible side effects. Most patients regarded clinical trials as useful, conducted to introduce a new treatment or drug. These results might be helpful for improving clinical researchers' understanding about clinical trial participants and useful when developing effective outreach strategies of recruitment for clinical trials.
Study limitations
This study had limitations due to a single group and lack of a control group. Further research should be performed to compare the results of: a) oncological patients who had never participated in a clinical trial vs oncological patients who have previously participated in a clinical trial; b) oncological patients who had never participated in a clinical trial vs healthy individuals.
